fluvoxamine has been researched along with Neurotic-Disorders* in 2 studies
1 trial(s) available for fluvoxamine and Neurotic-Disorders
Article | Year |
---|---|
An open clinical trial of fluvoxamine treatment of psychogenic excoriation.
The purpose of this study was to examine the safety and efficacy of fluvoxamine in the treatment of psychogenic (neurotic) skin excoriation. Fourteen subjects with psychogenic excoriation were given fluvoxamine in a 12-week, open-label trial after completion of the Structured Clinical Interview for DSM-IV. All subjects met DSM-IV criteria for at least one comorbid psychiatric disorder, with mood disorder the most common. Most subjects' excoriation had features of an impulse control disorder. Both completers (N = 7) and the entire group had significant improvement on the modified Yale-Brown Obsessive Compulsive Scale but no improvement on the Hamilton Rating Scale for Depression. In the self-report data, the seven completers had significant reduction in behaviors involving the skin (e.g., scratching, picking, gouging, or squeezing) and in global assessment of symptoms. Endpoint analysis of all 14 subjects' self-report data demonstrated significant improvement in the presence of skin sensations, skin appearance and lesions, behaviors involving the skin, control over skin behavior, and global assessment. The results of this preliminary open trial suggest that fluvoxamine may be effective in reducing psychogenic excoriation, and this effect seems to be independent of mood. Controlled studies are needed to confirm these findings. Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Female; Fluvoxamine; Humans; Male; Middle Aged; Neurotic Disorders; Obsessive-Compulsive Disorder; Skin Diseases; Treatment Outcome | 1999 |
1 other study(ies) available for fluvoxamine and Neurotic-Disorders
Article | Year |
---|---|
Predictors of course in obsessive-compulsive disorder: logistic regression versus Cox regression for recurrent events.
Two methods for predicting remissions in obsessive-compulsive disorder (OCD) treatment are evaluated. Y-BOCS measurements of 88 patients with a primary OCD (DSM-III-R) diagnosis were performed over a 16-week treatment period, and during three follow-ups.. Remission at any measurement was defined as a Y-BOCS score lower than thirteen combined with a reduction of seven points when compared with baseline. Logistic regression models were compared with a Cox regression for recurrent events model.. Logistic regression yielded different models at different evaluation times. The recurrent events model remained stable when fewer measurements were used. Higher baseline levels of neuroticism and more severe OCD symptoms were associated with a lower chance of remission, early age of onset and more depressive symptoms with a higher chance.. Choice of outcome time affects logistic regression prediction models. Recurrent events analysis uses all information on remissions and relapses. Short- and long-term predictors for OCD remission show overlap. Topics: Anti-Anxiety Agents; Behavior Therapy; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Desensitization, Psychologic; Fluvoxamine; Follow-Up Studies; Humans; Logistic Models; Neurotic Disorders; Obsessive-Compulsive Disorder; Outcome and Process Assessment, Health Care; Personality Inventory; Proportional Hazards Models; Psychometrics; Randomized Controlled Trials as Topic; Recurrence | 2007 |